Cited 0 times in
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2024-01-03T00:32:50Z | - |
dc.date.available | 2024-01-03T00:32:50Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 2152-2650 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197287 | - |
dc.description.abstract | Background: The Phase 3 IKEMA study (NCT03275285) demonstrated isatuximab (Isa) in combination with carfilzomib (K) and dexamethasone (d) significantly improved progression-free survival (PFS) in patients with relapsed multiple myeloma (MM) compared with Kd. A post-hoc analysis of East Asian patients in IKEMA evaluated the efficacy and safety of Isa-Kd versus Kd in this population and was previously published. Patients and methods: Patients with relapsed MM who had received 1 to 3 prior lines of therapy were randomized 3:2 to receive Isa-Kd or Kd. The primary endpoint was PFS, and key secondary endpoints included rate of very good partial response or better (≥VGPR), complete response (CR) rate, and minimal residual disease (MRD) negativity. Of the IKEMA overall population, 46 patients were of East Asian descent. This is an updated analysis of the efficacy and safety of Isa-Kd in East Asian patients, including data through 14 January 2022. Results: Isa-Kd continued to demonstrate improved efficacy and safety versus Kd in East Asian patients with relapsed MM, with improved PFS, rate of ≥VGPR, CR rate, and MRD negativity, that was consistent with the overall IKEMA population. The rate of Grade ≥3 treatment-emergent adverse events was also consistent with the prior analysis and overall IKEMA population. Conclusion: Based on the results of this analysis, Isa-Kd is a novel treatment option for East Asian patients with relapsed MM. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Dexamethasone / therapeutic use | - |
dc.subject.MESH | East Asian People | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Multiple Myeloma* | - |
dc.subject.MESH | Recurrence | - |
dc.title | Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yawara Kawano | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Chang Ki Min | - |
dc.contributor.googleauthor | Youngil Koh | - |
dc.contributor.googleauthor | Kenichi Ishizawa | - |
dc.contributor.googleauthor | Sung Hyun Kim | - |
dc.contributor.googleauthor | Shigeki Ito | - |
dc.contributor.googleauthor | Junji Tanaka | - |
dc.contributor.googleauthor | Michihiro Uchiyama | - |
dc.contributor.googleauthor | Tadao Ishida | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Philippe Moreau | - |
dc.contributor.googleauthor | Thomas Martin | - |
dc.contributor.googleauthor | Keisuke Tada | - |
dc.contributor.googleauthor | Marie-Laure Risse | - |
dc.contributor.googleauthor | Kenshi Suzuki | - |
dc.identifier.doi | 10.1016/j.clml.2023.06.011 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J04262 | - |
dc.identifier.eissn | 2152-2669 | - |
dc.identifier.pmid | 37479547 | - |
dc.subject.keyword | Relapsed MM | - |
dc.subject.keyword | Minimal residual disease | - |
dc.subject.keyword | Overall response | - |
dc.subject.keyword | Cytogenetic risk | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 23 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | e360 | - |
dc.citation.endPage | e367 | - |
dc.identifier.bibliographicCitation | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol.23(10) : e360-e367, 2023-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.